Treatment-Resistant Depression

Midwest CEPAC
May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
LAX Room
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Key Dates

Associated Materials